506 related articles for article (PubMed ID: 11259554)
1. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
4. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
McCluskie K; Klein U; Linnevers C; Ji YH; Yang A; Husfeld C; Thomas GR
J Pharmacol Exp Ther; 2006 Oct; 319(1):468-76. PubMed ID: 16861399
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
10. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
12. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
13. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
15. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Sanz MJ; Cortijo J; Taha MA; Cerdá-Nicolás M; Schatton E; Burgbacher B; Klar J; Tenor H; Schudt C; Issekutz AC; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2007 Oct; 152(4):481-92. PubMed ID: 17704822
[TBL] [Abstract][Full Text] [Related]
17. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
20. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.
Jones NA; Boswell-Smith V; Lever R; Page CP
Pulm Pharmacol Ther; 2005; 18(2):93-101. PubMed ID: 15649851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
